⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTHS News
Pelthos Therapeutics Inc.
Pelthos Therapeutics Announces CFO Transition
globenewswire.com
PTHS
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
globenewswire.com
PTHS
Form 8-K
sec.gov
PTHS
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
PTHS
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
globenewswire.com
PTHS
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
globenewswire.com
PTHS
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
PTHS
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
globenewswire.com
PTHS
HRZN
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
globenewswire.com
PTHS
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
globenewswire.com
PTHS